Why the study?
Members of the ACCP Perioperative Care PRN and ERAS Society presented an opinion to identify therapeutic options, generate research questions, propose collaborative practice opportunities, and highlight pharmacist-led cost savings within ERAS programs.
Clinical pharmacists play a critical collaborative role in optimizing pharmacotherapy, improving outcomes, and reducing costs within Enhanced Recovery After Surgery (ERAS) programs.
Expert opinion identifies perioperative therapeutic options; leaves open need for trials before changing practice.
One of the most durable approaches to perioperative enhanced recovery programming has culminated in the formation of perioperative organizations devoted to improvements in the quality of the surgical patient experience, such as the Enhanced Recovery After Surgery (ERAS®) Society. Members of the American College of Clinical Pharmacy (ACCP) Perioperative Care Practice and Research Network (PRN) and officials from the ERAS® Society present an opinion that: (1) identifies therapeutic options within each pharmacotherapy-intensive area of ERAS®; (2) generates applied research questions that would allow for comparative analyses of pharmacotherapy options within ERAS® programs; (3) proposes collaborative practice opportunities between key stakeholders in the surgical journey and clinical pharmacists to manage drug therapy problems and research questions; and (4) highlights examples of pharmacist-led cost savings attributed to ERAS® implementation. Clinical pharmacists, working in this manner with the perioperative team across the care continuum, have optimized pharmacotherapy towards measurable outcomes improvements, and stand ready to partner with inter-professional stakeholders and organizations to advance the care of our mutual patients.
No takes yet. Share an insight, caveat, or question.
Lovely et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: